Polynovo Ltd (ASX: PNV) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.40 billion
P/E Ratio 2,500.00
Dividend Yield N/A
Shares Outstanding 661.69 million
Earnings per share 0.001
Dividend per share N/A
Year To Date Return 42.95%
Earnings Yield 0.04%
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Polynovo Ltd (ASX: PNV)
Latest News

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

How have Polynovo shares been performing since leaving the ASX 200?

The medical device company's shares can't seem to catch a break this week.

Read more »

stylised silhouette of a bear on financial graph background
Share Market News

These are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Share Market News

5 things to watch on the ASX 200 on Monday

The ASX 200 looks set to start the week in the red...

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

These were the best performing ASX 200 shares last week

These ASX 200 shares were on form last week despite the market selloff...

Read more »

A female executive smiles as she carries out business on her mobile phone.
Share Market News

Buying the dip: 3 ASX All Ord shares insiders are loading up on

Insiders are taking advantage of the fire sale...

Read more »

A smug young man points to his chest feeling proud that he invested in Polynovo shares which are rising today amid a market sell-off
Healthcare Shares

Why is the Polynovo share price rising while other ASX 200 stocks are plummeting?

Polynovo shares are avoiding today's market sell-off.

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Share Gainers

Why Australian Clinical Labs, Lake Resources, PolyNovo, and ResApp are rising

These ASX shares are pushing higher despite the market selloff...

Read more »

The words short selling in red against a black background
Share Market News

These are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

PNV ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Polynovo Ltd

Polynovo Ltd (ASX: PNV) is an Australian-based medical device company that designs, develops and manufactures dermal regeneration solutions.

Its flagship patented NovoSorb biodegradable polymer technology is used to develop innovative medical devices that help surgeons treat patients with traumatic wounds. The company also has a development program covering breast sling, hernia, and orthopaedic applications.

Investors in the Polynovo share price will be happy to know the company is preparing for growth by expanding its manufacturing facility and headquarters in Melbourne, and establishing high quality processes that enable product innovation.

PNV Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 Aug 2022 $2.12 $-0.06 -2.75% 1,276,859 $2.16 $2.18 $2.07
17 Aug 2022 $2.18 $0.08 3.81% 2,336,355 $2.08 $2.22 $2.04
16 Aug 2022 $2.10 $-0.04 -1.87% 1,650,058 $2.14 $2.20 $2.10
15 Aug 2022 $2.14 $0.04 1.90% 1,711,266 $2.16 $2.21 $2.12
12 Aug 2022 $2.10 $-0.08 -3.67% 2,419,869 $2.15 $2.22 $2.05
11 Aug 2022 $2.18 $0.06 2.83% 2,302,685 $2.17 $2.25 $2.12
10 Aug 2022 $2.12 $0.00 0.00% 4,287,886 $2.11 $2.14 $2.04
09 Aug 2022 $2.12 $0.10 4.95% 3,736,801 $2.01 $2.20 $2.01
08 Aug 2022 $2.02 $0.11 5.76% 3,936,654 $1.97 $2.05 $1.92
05 Aug 2022 $1.91 $0.10 5.52% 3,089,444 $1.81 $1.92 $1.79
04 Aug 2022 $1.81 $0.10 5.85% 3,814,891 $1.73 $1.84 $1.72
03 Aug 2022 $1.71 $0.13 8.23% 2,732,225 $1.60 $1.71 $1.55
02 Aug 2022 $1.58 $-0.02 -1.25% 1,179,923 $1.59 $1.60 $1.55
01 Aug 2022 $1.60 $-0.04 -2.44% 2,414,531 $1.67 $1.71 $1.60
29 Jul 2022 $1.64 $0.13 8.61% 3,157,111 $1.52 $1.64 $1.51
28 Jul 2022 $1.51 $0.09 6.34% 2,443,154 $1.46 $1.51 $1.44
27 Jul 2022 $1.42 $-0.04 -2.74% 2,527,081 $1.41 $1.45 $1.39
26 Jul 2022 $1.46 $-0.03 -2.01% 3,470,244 $1.48 $1.49 $1.36
25 Jul 2022 $1.49 $-0.24 -13.91% 4,409,315 $1.69 $1.70 $1.48
22 Jul 2022 $1.73 $0.15 9.49% 4,393,009 $1.60 $1.73 $1.56
21 Jul 2022 $1.58 $0.01 0.63% 2,889,890 $1.58 $1.63 $1.56
20 Jul 2022 $1.58 $0.09 6.06% 3,364,793 $1.52 $1.58 $1.52

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Jun 2022 David Williams Buy 21 $24,245
On-market trade.
06 Jun 2022 David Williams Buy 228 $259,897
On-market trade.
03 Jun 2022 David Williams Buy 266 $317,352
On-market trade.
02 Jun 2022 David Williams Buy 833 $956,171
On-market trade.
01 Jun 2022 David Williams Buy 79 $94,271
On-market trade.
26 May 2022 David Williams Buy 302 $359,653
On-market trade.
25 May 2022 David Williams Buy 206 $242,522
On-market trade.
23 May 2022 David Williams Buy 300 $375,999
On-market trade.
19 May 2022 David Williams Buy 100 $120,000
On-market trade.
18 May 2022 David Williams Buy 346 $430,361
On-market trade.
16 May 2022 David Williams Buy 405 $514,307
On-market trade.
13 May 2022 David Williams Buy 181 $231,392
On-market trade.
12 May 2022 David Williams Buy 218 $247,803
On-market trade.
11 May 2022 David Williams Buy 249 $265,947
On-market trade.
10 May 2022 David Williams Buy 200 $213,597
On-market trade.
09 May 2022 David Williams Buy 250 $227,500
On-market trade.
06 May 2022 David Williams Buy 1 $899,931
On-market trade.
06 May 2022 Christine Emmanuel Buy 115 $98,337
On-market trade.
05 May 2022 Andrew Lumsden Buy 100 $87,314
On-market trade.
05 May 2022 David Williams Buy 500 $434,467
On-market trade.
05 Nov 2021 Paul Brennan Transfer 4 $7,344,841
Off-market transfer. Assuming 4,185,095 direct shares transferred to indirect shares
05 Nov 2021 Paul Brennan Transfer 4 $7,344,841
Off-market transfer. Assuming 4,185,095 direct shares transferred to indirect shares

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising. He has 30+ years experience working with and advising ASX-listed companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Chairman of RMA Global Limited and is Managing Director of corporate advisory firm Kidder Williams Ltd.
Mr Bruce Rathie Non-Executive Director Feb 2010
Mr Rathie is an experienced Company Director with a finance and legal background. He practised as a partner in a large legal firm and acted as Senior Corporate Counsel to Bell Resources Limited in its early years. He has a 15-year investment banking career. When Head of the Industrial Franchise Group at Salomon Smith Barney he led Salomon's roles in the Federal Government's privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1). He now has over 20 years experience as a full time professional Nonexecutive Director. He is currently Chairman of Capricorn Mutual Limited and a Non-executive Director of Capricorn Society Limited and Australian Meat Processors Limited. In the medical device space, he was previously Director of Compumedics Limited and USCOM Limited.
Dr Robyn Elliott Non-Executive Director Oct 2019
Dr Elliott is currently Executive Director, Strategic Fractionation Program Delivery at CSL Behring, a global role that is responsible for business value delivery from a billion-dollar capital expansion portfolio. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding. Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally.
Dr David McQuillan Non-Executive Director Aug 2012
Dr McQuillan has technical, medical, scientific, and regulatory knowledge, as well as merger and acquisition expertise. Dr McQuillan was with LifeCell Inc/Kinetic Concepts Inc (KCI) for 12 years, holding a number of senior roles, including Vice President for Research and Development at LifeCell and Senior Vice President of Advanced Research and Technology at KCI. He was Chief Science Officer for TELA Bio, a VC-funded development stage biotechnology company from 2013 to 2015. He is currently a Non-executive Director for Cell Care Therapeutics Inc (a privately held stem cell company based in Monrovia, CA) and Nonexecutive Director and Co-Founder of ECM Technologies Inc (a privately held biotechnology company based in Houston, TX).
Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
Mr Lumsden is a Chartered Accountant and finance executive with more than 20 years experience locally and internationally. Mr Lumsden is currently Global Chief Operating Officer of Wellcom Group Pty Ltd (formerly Wellcom Group Limited) having previously held the roles of Chief Financial Officer and Company Secretary. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers.
Mr Leon Hoare Non-Executive Director Jan 2016
Mr Hoare is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of Smith & Nephew's largest global subsidiaries outside the USA. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb (medical devices), and as Vice Chair of Australia's peak medical device body, Medical Technology Association of Australia.
Ms Christine Emmanuel Non-Executive Director May 2020
Ms Emmanuel is a patent and trademark attorney, and a business development professional with more than 30 years local and international experience. She is Vice President of the Board of the Institute of Patent and Trade Mark Attorneys of Australia on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments International. Ms Emmanuel is currently IP & Commercialisation manager at RMIT University and was previously Executive Manager of Business Development and Commercial at the CSIRO, having founded and led the management of CSIRO's IP portfolio for over 10 years and managed the growth of the CSIRO equity portfolio for the last 5 years. Previously she was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK) and Davies Collison
Mr Jan-Marcel Gielen Chief Financial OfficerCompany Secretary Dec 2018
Mr Swami Raote Chief Executive Officer Jul 2022
Swami Raote Chief Executive Officer
Jan-Marcel Gielen Chief Financial OfficerCompany Secretary
Anthony Kaye Chief Operating Officer

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 86,192,215 13.03%
J P Morgan Nominees Australia Pty Limited 41,780,382 6.32%
Citicorp Nominees Pty Limited 27,212,802 4.11%
Moggs Creek Pty Ltd <Moggs Creek Super A/C> 17,800,000 2.69%
National Nominees Limited 16,084,276 2.43%
Lateral Innovations Pty Ltd <Trust A/C> 10,924,103 1.65%
Mr Anthony Shane Kittel + Mrs Michele Therese Kittel <Kittel Family Super A/C> 7,960,000 1.20%
BNP Paribas Noms Pty Ltd <Drp> 7,944,172 1.20%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 6,340,183 0.96%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 5,300,974 0.80%
Mr Paul Gerard Brennan 4,185,095 0.63%
Ms Simone Maree Beks 4,185,095 0.63%
Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.62%
Netwealth Investments Limited <Wrap Services A/C> 4,019,409 0.61%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 3,397,939 0.51%
Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C> 3,374,840 0.51%
Mr Paul Lappin + Mrs Siobhan Lyons <Lappin Super Fund A/C> 3,154,631 0.48%
Mr David Kenley 3,139,855 0.47%
Dr Marcus James Dermot Wagstaff + Mrs Lara Kate Wagstaff 3,056,377 0.46%
Mr Laurent Fossaert 3,014,172 0.46%